A while back one of IPIX's medical experts said that the surface had not barely been scratched in regard to the uses for Brilacidin. If that wasn't extremely sage and correct advice, I don't know what is!
Hard to believe that in Feb none of us were even considering Brilacidin as a treatment for a virus, yet now we are discussing the possibility that it could become the go-to drug for a whole slew of viruses, to include CV19 and the flu. The revenue numbers if that comes to pass are staggering.
In addition, we now know that Brilacidin should be given some prime attention as a therapeutic for kidney conditions, possibly head inflammation for the other virus studies mentioned in the PR today, and even Ebola.
We also should have very positive news soon in regards to human lung tissue testing. That should open the door to COPD and Asthma treatment, not to mention other lung disorders.
Then we find out that CV appears to be a blood vessel attacker and again Brilacidin appears to fill the niche to defend the body against that. Brainstorming idea - what about a combo drug of Brilacidin and Kevetrin to work against leukemia?
So now we have head, lung, kidney, bowel, and blood vessel conditions already being discussed as possible Brilacidin treatment areas.
AND ALL OF THE ABOVE WAS NOT KNOWN PRIOR TO FEB. THIS HAS ALL HAPPENED THRU TESTING OF JUST A FEW MONTHS!!! And now the RBL wants to do a pan-corona study and who knows what the other facilities about to publish peer-reviewed articles found while testing B?
We know of dermatology, eye/ear drops, and antibiotic indications that should be right up Brilacidin's alley as well.
If this doesn't equate to a drug that has as wide a spectrum of uses as one might find in any drug to date, I would be surprised.
So does anyone really believe (assuming IPIX does get a large sum of grant money for further study) Brilacidin shouldn't be kept in house, along with its many indications, for the current time? Or at least until the current investigations for Brilacidin are wrapped up? What else will come to light, as it seems extremely plausible that further uses will be uncovered with the more intense investigations planned for the future?
People talk about value and most longs don't want to sound like pumpers so nobody goes crazy, but in light of the above and assuming that B and K do most everything we think that may be able to do, if someone wanted to get Leo's attention I do not think a single digit buyout offer would even make him blink, nor would a low end double digit offer. What the BP is getting is not a bio startup, but with Brilacidin and Kevetrin they could be getting a decent sized BP thru the acquisition of IPIX. Some of them are loaded with cash, over $50B, so I believe a good chunk of that will be needed to get Leo to blink. May not happen, no worries, as then IPIX will become the largest paying dividend stock in history. My opinion only and why figures of anything under $25 don't even get my attention in terms of starting to unload my position.
Hard to believe that in Feb none of us were even considering Brilacidin as a treatment for a virus, yet now we are discussing the possibility that it could become the go-to drug for a whole slew of viruses, to include CV19 and the flu. The revenue numbers if that comes to pass are staggering.
In addition, we now know that Brilacidin should be given some prime attention as a therapeutic for kidney conditions, possibly head inflammation for the other virus studies mentioned in the PR today, and even Ebola.
We also should have very positive news soon in regards to human lung tissue testing. That should open the door to COPD and Asthma treatment, not to mention other lung disorders.
Then we find out that CV appears to be a blood vessel attacker and again Brilacidin appears to fill the niche to defend the body against that. Brainstorming idea - what about a combo drug of Brilacidin and Kevetrin to work against leukemia?
So now we have head, lung, kidney, bowel, and blood vessel conditions already being discussed as possible Brilacidin treatment areas.
AND ALL OF THE ABOVE WAS NOT KNOWN PRIOR TO FEB. THIS HAS ALL HAPPENED THRU TESTING OF JUST A FEW MONTHS!!! And now the RBL wants to do a pan-corona study and who knows what the other facilities about to publish peer-reviewed articles found while testing B?
We know of dermatology, eye/ear drops, and antibiotic indications that should be right up Brilacidin's alley as well.
If this doesn't equate to a drug that has as wide a spectrum of uses as one might find in any drug to date, I would be surprised.
So does anyone really believe (assuming IPIX does get a large sum of grant money for further study) Brilacidin shouldn't be kept in house, along with its many indications, for the current time? Or at least until the current investigations for Brilacidin are wrapped up? What else will come to light, as it seems extremely plausible that further uses will be uncovered with the more intense investigations planned for the future?
People talk about value and most longs don't want to sound like pumpers so nobody goes crazy, but in light of the above and assuming that B and K do most everything we think that may be able to do, if someone wanted to get Leo's attention I do not think a single digit buyout offer would even make him blink, nor would a low end double digit offer. What the BP is getting is not a bio startup, but with Brilacidin and Kevetrin they could be getting a decent sized BP thru the acquisition of IPIX. Some of them are loaded with cash, over $50B, so I believe a good chunk of that will be needed to get Leo to blink. May not happen, no worries, as then IPIX will become the largest paying dividend stock in history. My opinion only and why figures of anything under $25 don't even get my attention in terms of starting to unload my position.
14
